← All trials
NCT06605118
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 4, 2024
- Primary completion
- Nov 30, 2027
- Completion date
- Mar 31, 2028
- First posted
- Sep 20, 2024
- Last posted
- Nov 7, 2024
- Enrollment
- 8000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- George Washington UniversityLead sponsor
- University of Alabama, BirminghamCollaborator
- University of Alabama, BirminghamOfficial
- George Washington UniversityOfficial
- University of North Carolina at Chapel HillOfficial
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.